AnaMar’s strength in drug discovery and development builds on a deep understanding in 5-HT2B receptor biology and fibrosis. We are developing our first-in-class, orally bioavailable, peripherally-acting 5-HT2B receptor antagonists to prevent and reverse pathological fibrosis.

AnaMar’s 5-HT2B receptor antagonists are protected worldwide by patents in territories of commercial relevance. AnaMar’s patent strategy is global, and our patent portfolio includes a wide range of additional 5-HT2B receptor antagonists.